Yahoo · Sep 4, 2026
United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CO
NASDAQ · CORT
Corcept Therapeutics Incorporated
Healthcare · Biotechnology
$114.92
Up+$1.31 (+1.14%)
Updated Sep 11, 2026, 1:40 PM
SID Score
6.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 9.17B
- P/E ratio
- 85.77
- Dividend yield
- 0.00%
- 52-week range
- $28.66 – $126.38
- Volume
- 683.01K
- Avg. volume
- 846.24K
Price performance
CORT price history
1M range · 20 trading sessions · Daily adjusted prices
CORT closed at $114.92 after 20 trading sessions, up 3.99% for the selected period.
- Last close
- $114.92
- Period change
- +3.99%
- Period low
- $110.43
- Period high
- $123.57
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $114.42 | $116.99 | $113.20 | $114.92 | 683.01K |
| Sep 9, 2026 | $114.20 | $117.50 | $113.77 | $115.70 | 572.05K |
| Sep 8, 2026 | $108.87 | $115.28 | $108.25 | $113.98 | 1.05M |
| Sep 4, 2026 | $110.59 | $112.13 | $109.26 | $111.62 | 604.56K |
| Sep 3, 2026 | $110.38 | $114.6051 | $109.43 | $112.80 | 611.21K |
| Sep 2, 2026 | $113.38 | $115.78 | $108.725 | $110.43 | 960.83K |
| Sep 1, 2026 | $113.92 | $115.85 | $111.13 | $113.38 | 1.11M |
| Aug 31, 2026 | $113.64 | $114.525 | $111.23 | $113.35 | 636.57K |
| Aug 28, 2026 | $117.14 | $118.6672 | $112.97 | $113.88 | 917.93K |
| Aug 27, 2026 | $119.25 | $121.295 | $116.70 | $116.93 | 642.41K |
| Aug 26, 2026 | $122.57 | $123.64 | $119.74 | $119.80 | 981.09K |
| Aug 25, 2026 | $124.89 | $126.3833 | $122.00 | $123.57 | 981.69K |
| Aug 24, 2026 | $120.56 | $124.14 | $119.174 | $123.24 | 1.01M |
| Aug 21, 2026 | $121.48 | $123.4361 | $120.56 | $122.25 | 656.44K |
| Aug 20, 2026 | $118.11 | $121.72 | $116.3132 | $121.05 | 787.41K |
| Aug 19, 2026 | $119.37 | $121.11 | $118.37 | $119.02 | 859.7K |
| Aug 18, 2026 | $116.595 | $119.95 | $116.595 | $118.10 | 804.03K |
| Aug 17, 2026 | $115.00 | $117.49 | $114.385 | $117.17 | 541.1K |
| Aug 14, 2026 | $110.61 | $114.899 | $110.085 | $114.47 | 728.92K |
| Aug 13, 2026 | $112.53 | $113.00 | $110.23 | $110.51 | 740.46K |
Latest CORT news
The latest Smart Investors Daily articles mentioning CORT.
Stock researchCompany · Overview
CORT research
Overview
Company profile and research snapshot.
Company profile
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $140.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | Canaccord Genuity | Buy | — |
| Jul 30, 2026 | Piper Sandler | Overweight | — |
| Jul 30, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 29, 2026 | Canaccord Genuity | Buy | — |
| Jul 27, 2026 | Wolfe Research | Underperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 2, 2026
1 Growth Stock Set to Flourishand 2 We Brush Off
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Yahoo · Aug 28, 2026
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SeekingAlpha · Aug 21, 2026
Like The Knick's, Corcept Rebounded And Is Crushing It
Corcept has the opportunity to be a game changer not just in cancer medications but across many diseases. Check out why CORT stock is a buy.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
